Decreased Hyocholic Acid and Lysophosphatidylcholine Induce Elevated Blood Glucose in a Transgenic Porcine Model of Metabolic Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Plasma Sample Collection and Biochemical Tests
2.3. Metabolite Extraction
2.4. Untargeted HPLC-MS Analysis
2.5. Data Processing and Statistical Analysis
2.6. Immunoblotting
3. Results
3.1. Weight Change and Plasma Biochemical Parameters
3.2. Metabolomic and Lipidomic Profiling of Pig Plasma
3.3. Biomarkers of Obesity and Diabetes in PIGinH11 Pigs
4. Discussion
5. Limitations of the Study
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Alsoud, L.O.; Soares, N.C.; Al-Hroub, H.M.; Mousa, M.; Kasabri, V.; Bulatova, N.; Suyagh, M.; Alzoubi, K.H.; El-Huneidi, W.; Abu-Irmaileh, B.; et al. Identification of Insulin Resistance Biomarkers in Metabolic Syndrome Detected by UHPLC-ESI-QTOF-MS. Metabolites 2022, 12, 508. [Google Scholar] [CrossRef] [PubMed]
- Yang, Q.; Vijayakumar, A.; Kahn, B.B. Metabolites as regulators of insulin sensitivity and metabolism. Nat. Rev. Mol. Cell Biol. 2018, 19, 654–672. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.L.; Xia, J.H.; Zhang, Y.Y.; Fan, J.G.; Wang, H.; Yuan, J.; Zhao, Z.Z.; Pan, Q.; Mu, Y.L.; Xin, L.L.; et al. Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Sci. Rep. 2015, 5, 13980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Umeyama, K.; Watanabe, M.; Saito, H.; Kurome, M.; Tohi, S.; Matsunari, H.; Miki, K.; Nagashima, H. Dominant-negative mutant hepatocyte nuclear factor 1alpha induces diabetes in transgenic-cloned pigs. Transgenic Res. 2009, 18, 697–706. [Google Scholar] [CrossRef] [PubMed]
- Renner, S.; Fehlings, C.; Herbach, N.; Hofmann, A.; von Waldthausen, D.C.; Kessler, B.; Ulrichs, K.; Chodnevskaja, I.; Moskalenko, V.; Amselgruber, W.; et al. Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010, 59, 1228–1238. [Google Scholar] [CrossRef] [Green Version]
- Renner, S.; Braun-Reichhart, C.; Blutke, A.; Herbach, N.; Emrich, D.; Streckel, E.; Wünsch, A.; Kessler, B.; Kurome, M.; Bähr, A.; et al. Permanent neonatal diabetes in INS(C94Y) transgenic pigs. Diabetes 2013, 62, 1505–1511. [Google Scholar] [CrossRef] [Green Version]
- Zhang, K.; Tao, C.; Xu, J.; Ruan, J.; Xia, J.; Zhu, W.; Xin, L.; Ye, H.; Xie, N.; Xia, B.; et al. CD8+ T Cells Involved in Metabolic Inflammation in Visceral Adipose Tissue and Liver of Transgenic Pigs. Front. Immunol. 2021, 12, 690069. [Google Scholar] [CrossRef]
- Ramzan, I.; Ardavani, A.; Vanweert, F.; Mellett, A.; Atherton, P.J.; Idris, I. The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis. Nutrients 2022, 14, 4411. [Google Scholar] [CrossRef]
- Sun, Y.; Gao, H.Y.; Fan, Z.Y.; He, Y.; Yan, Y.X. Metabolomics Signatures in Type 2 Diabetes: A Systematic Review and Integrative Analysis. J. Clin. Endocrinol. Metab. 2020, 105, dgz240. [Google Scholar] [CrossRef]
- Dambrova, M.; Makrecka-Kuka, M.; Kuka, J.; Vilskersts, R.; Nordberg, D.; Attwood, M.M.; Smesny, S.; Sen, Z.D.; Guo, A.C.; Oler, E.; et al. Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacol. Rev. 2022, 74, 506–551. [Google Scholar] [CrossRef]
- Sobczak, A.I.S.; Blindauer, C.A.; Stewart, A.J. Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. Nutrients 2019, 11, 2022. [Google Scholar] [CrossRef] [Green Version]
- Nie, C.; He, T.; Zhang, W.; Zhang, G.; Ma, X. Branched Chain Amino Acids: Beyond Nutrition Metabolism. Int. J. Mol. Sci. 2018, 19, 954. [Google Scholar] [CrossRef] [Green Version]
- Zhao, H.; Zhang, F.; Sun, D.; Wang, X.; Zhang, X.; Zhang, J.; Yan, F.; Huang, C.; Xie, H.; Lin, C.; et al. Branched-Chain Amino Acids Exacerbate Obesity-Related Hepatic Glucose and Lipid Metabolic Disorders via Attenuating Akt2 Signaling. Diabetes 2020, 69, 1164–1177. [Google Scholar] [CrossRef]
- Apontes, P.; Liu, Z.; Su, K.; Benard, O.; Youn, D.Y.; Li, X.; Li, W.; Mirza, R.H.; Bastie, C.C.; Jelicks, L.A.; et al. Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. Diabetes 2014, 63, 3626–3636. [Google Scholar] [CrossRef] [Green Version]
- Kitada, M.; Ogura, Y.; Monno, I.; Koya, D. The impact of dietary protein intake on longevity and metabolic health. EBioMedicine 2019, 43, 632–640. [Google Scholar] [CrossRef] [Green Version]
- Horvath, S.E.; Daum, G. Lipids of mitochondria. Prog. Lipid Res. 2013, 52, 590–614. [Google Scholar] [CrossRef]
- Frigerio, G.; Favero, C.; Savino, D.; Mercadante, R.; Albetti, B.; Dioni, L.; Vigna, L.; Bollati, V.; Pesatori, A.C.; Fustinoni, S. Plasma Metabolomic Profiling in 1391 Subjects with Overweight and Obesity from the SPHERE Study. Metabolites 2021, 11, 194. [Google Scholar] [CrossRef]
- Tulipani, S.; Palau-Rodriguez, M.; Alonso, A.M.; Cardona, F.; Marco-Ramell, A.; Zonja, B.; de Alda, M.L.; Muñoz-Garach, A.; Sanchez-Pla, A.; Tinahones, F.J.; et al. Biomarkers of Morbid Obesity and Prediabetes by Metabolomic Profiling of Human Discordant Phenotypes. Clin. Chim. Acta 2016, 463, 53–61. [Google Scholar] [CrossRef]
- Wang-Sattler, R.; Yu, Z.; Herder, C.; Messias, A.C.; Floegel, A.; He, Y.; Heim, K.; Campillos, M.; Holzapfel, C.; Thorand, B.; et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol. 2012, 8, 615. [Google Scholar] [CrossRef]
- Fikri, A.M.; Smyth, R.; Kumar, V.; Al-Abadla, Z.; Abusnana, S.; Munday, M.R. Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE’s obese national population using targeted metabolomics. Sci. Rep. 2020, 10, 17616. [Google Scholar] [CrossRef]
- Long, J.; Yang, Z.; Wang, L.; Han, Y.; Peng, C.; Yan, C.; Yan, D. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: A systematic review and meta-analysis. BMC Endocr. Disord. 2020, 20, 174. [Google Scholar] [CrossRef] [PubMed]
- Renner, S.; Römisch-Margl, W.; Prehn, C.; Krebs, S.; Adamski, J.; Göke, B.; Blum, H.; Suhre, K.; Roscher, A.A.; Wolf, E. Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced β-cell mass. Diabetes 2012, 61, 2166–2175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Y.; Orešič, M.; Leivonen, M.; Gopalacharyulu, P.; Hyysalo, J.; Arola, J.; Verrijken, A.; Francque, S.; Van Gaal, L.; Hyötyläinen, T.; et al. Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. Clin. Gastroenterol. Hepatol. 2016, 14, 1463–1472.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luukkonen, P.K.; Nick, A.; Hölttä-Vuori, M.; Thiele, C.; Isokuortti, E.; Lallukka-Brück, S.; Zhou, Y.; Hakkarainen, A.; Lundbom, N.; Peltonen, M.; et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight 2019, 4, e127902. [Google Scholar] [CrossRef] [PubMed]
- Matsuzaka, T.; Kuba, M.; Koyasu, S.; Yamamoto, Y.; Motomura, K.; Arulmozhiraja, S.; Ohno, H.; Sharma, R.; Shimura, T.; Okajima, Y.; et al. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. Hepatology 2020, 71, 1609–1625. [Google Scholar] [CrossRef]
- Chaurasia, B.; Tippetts, T.S.; Mayoral Monibas, R.; Liu, J.; Li, Y.; Wang, L.; Wilkerson, J.L.; Sweeney, C.R.; Pereira, R.F.; Sumida, D.H.; et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 2019, 365, 386–392. [Google Scholar] [CrossRef]
- Barber, M.N.; Risis, S.; Yang, C.; Meikle, P.J.; Staples, M.; Febbraio, M.A.; Bruce, C.R. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE 2012, 7, e41456. [Google Scholar] [CrossRef] [Green Version]
- Tan, S.T.; Ramesh, T.; Toh, X.R.; Nguyen, L.N. Emerging roles of lysophospholipids in health and disease. Prog Lipid Res 2020, 80, 101068. [Google Scholar] [CrossRef]
- Yea, K.; Kim, J.; Yoon, J.H.; Kwon, T.; Kim, J.H.; Lee, B.D.; Lee, H.J.; Lee, S.J.; Kim, J.I.; Lee, T.G.; et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J. Biol. Chem. 2009, 284, 33833–33840. [Google Scholar] [CrossRef] [Green Version]
- Overton, H.A.; Fyfe, M.C.; Reynet, C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 2008, 153 (Suppl. S1), S76–S81. [Google Scholar] [CrossRef]
- Soga, T.; Ohishi, T.; Matsui, T.; Saito, T.; Matsumoto, M.; Takasaki, J.; Matsumoto, S.; Kamohara, M.; Hiyama, H.; Yoshida, S.; et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 2005, 326, 744–751. [Google Scholar] [CrossRef]
- Overton, H.A.; Babbs, A.J.; Doel, S.M.; Fyfe, M.C.; Gardner, L.S.; Griffin, G.; Jackson, H.C.; Procter, M.J.; Rasamison, C.M.; Tang-Christensen, M.; et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006, 3, 167–175. [Google Scholar] [CrossRef] [Green Version]
- Drzazga, A.; Okulus, M.; Rychlicka, M.; Biegala, L.; Gliszczynska, A.; Gendaszewska-Darmach, E. Lysophosphatidylcholine Containing Anisic Acid Is Able to Stimulate Insulin Secretion Targeting G Protein Coupled Receptors. Nutrients 2020, 12, 1173. [Google Scholar] [CrossRef]
- Birge, R.B.; Boeltz, S.; Kumar, S.; Carlson, J.; Wanderley, J.; Calianese, D.; Barcinski, M.; Brekken, R.A.; Huang, X.; Hutchins, J.T.; et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016, 23, 962–978. [Google Scholar] [CrossRef] [Green Version]
- Grace, S.L.; Barry-Bianchi, S.; Stewart, D.E.; Rukholm, E.; Nolan, R.P. Physical activity behavior, motivational readiness and self-efficacy among Ontarians with cardiovascular disease and diabetes. J. Behav. Med. 2007, 30, 21–29. [Google Scholar] [CrossRef]
- Jové, M.; Tibau, J.; Serrano, J.C.; Berdún, R.; Rodríguez-Palmero, M.; Font-I-Furnols, M.; Cassanyé, A.; Rodriguez-Mortera, R.; Sol, J.; Rassendren, H.; et al. Molecular phenomics of a high-calorie diet-induced porcine model of prepubertal obesity. J. Nutr. Biochem. 2020, 83, 108393. [Google Scholar] [CrossRef]
- Zheng, X.; Chen, T.; Zhao, A.; Ning, Z.; Kuang, J.; Wang, S.; You, Y.; Bao, Y.; Ma, X.; Yu, H.; et al. Hyocholic acid species as novel biomarkers for metabolic disorders. Nat. Commun. 2021, 12, 1487. [Google Scholar] [CrossRef]
- Jia, W.; Rajani, C.; Zheng, X.; Jia, W. Hyocholic acid and glycemic regulation: Comments on ‘Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism’. J. Mol. Cell Biol. 2021, 13, 460–462. [Google Scholar] [CrossRef]
- Zheng, X.; Chen, T.; Jiang, R.; Zhao, A.; Wu, Q.; Kuang, J.; Sun, D.; Ren, Z.; Li, M.; Zhao, M.; et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021, 33, 791–803.e7. [Google Scholar] [CrossRef]
- Albaugh, V.L.; Banan, B.; Antoun, J.; Xiong, Y.; Guo, Y.; Ping, J.; Alikhan, M.; Clements, B.A.; Abumrad, N.N.; Flynn, C.R. Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery. Gastroenterology 2019, 156, 1041–1051.e4. [Google Scholar] [CrossRef]
- Yan, X.; Li, P.; Tang, Z.; Feng, B. The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance. BMC Endocr. Disord. 2017, 17, 60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Z.Z.; Gerszten, R.E. Metabolomics and Proteomics in Type 2 Diabetes. Circ. Res. 2020, 126, 1613–1627. [Google Scholar] [CrossRef] [PubMed]
- Bar, N.; Korem, T.; Weissbrod, O.; Zeevi, D.; Rothschild, D.; Leviatan, S.; Kosower, N.; Lotan-Pompan, M.; Weinberger, A.; Le Roy, C.I.; et al. A reference map of potential determinants for the human serum metabolome. Nature 2020, 588, 135–140. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Covarrubias, V.; Martínez-Martínez, E.; Del Bosque-Plata, L. The Potential of Metabolomics in Biomedical Applications. Metabolites 2022, 12, 194. [Google Scholar] [CrossRef]
Var | WT-0 | WT-2 | TG-0 | TG-2 | dWT | dTG | PWT-2/WT-0 | PTG-2/TG-0 | PTG-0/WT-0 | PTG-2/WT-2 |
---|---|---|---|---|---|---|---|---|---|---|
Weight (kg) | 29.1 ± 5.1 | 50.2 ± 6.7 | 29.5 ± 5.2 | 48.8 ± 7.5 | 21.2 ± 7.9 | 19.3 ± 5.9 | <0.001 | <0.001 | 0.852 | 0.662 |
Glu (mmol/L) | 4.8 ± 0.7 | 6.1 ± 1.6 | 7.4 ± 1.7 | 7.6 ± 0.8 | 1.3 ± 1.4 | 0.1 ± 1.4 | 0.013 | 0.813 | <0.001 | 0.022 |
Ins (μIU/mL) | 40.4 ± 15.9 | 64.3 ± 13.0 | 101.6 ± 56.7 | 62.0 ± 10.6 | 23.9 ± 15.2 | −39.6 ± 52.7 | <0.001 | 0.041 | 0.008 | 0.662 |
Tg (mmol/L) | 0.4 ± 0.1 | 0.4 ± 0.2 | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.0 ± 0.2 | −0.0 ± 0.1 | 0.872 | 0.216 | 0.166 | 0.651 |
Tc (mmol/L) | 2.0 ± 0.5 | 2.6 ± 0.5 | 1.9 ± 0.5 | 2.4 ± 0.5 | 0.6 ± 0.6 | 0.5 ± 0.5 | 0.015 | 0.009 | 0.656 | 0.325 |
Hdl (mmol/L) | 0.8 ± 0.2 | 1.4 ± 0.3 | 0.9 ± 0.1 | 1.1 ± 0.2 | 0.5 ± 0.3 | 0.2 ± 0.1 | <0.001 | <0.001 | 0.906 | 0.023 |
Ldl (mmol/L) | 0.9 ± 0.2 | 0.7 ± 0.2 | 0.7 ± 0.3 | 0.7 ± 0.2 | −0.1 ± 0.3 | −0.1 ± 0.3 | 0.116 | 0.349 | 0.298 | 0.488 |
GLP-1 (pmol/l) | 0.8 ± 0.2 | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.9 ± 0.5 | −0.2 ± 0.2 | 0.3 ± 0.6 | 0.008 | 0.130 | 0.025 | 0.113 |
Group | Metabolomics | Lipidomics | ||||
---|---|---|---|---|---|---|
All | Up | Down | All | Up | Down | |
WT-2 vs. WT-0 | 273 | 139 | 134 | 228 | 106 | 122 |
TG-2 vs. TG-0 | 269 | 120 | 149 | 244 | 144 | 100 |
TG-0 vs. WT-0 | 155 | 56 | 99 | 226 | 103 | 123 |
TG-2 vs. WT-2 | 172 | 62 | 110 | 222 | 127 | 95 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Xu, J.; Zhang, K.; Qiu, B.; Liu, J.; Liu, X.; Yang, S.; Xiao, X. Decreased Hyocholic Acid and Lysophosphatidylcholine Induce Elevated Blood Glucose in a Transgenic Porcine Model of Metabolic Disease. Metabolites 2022, 12, 1164. https://doi.org/10.3390/metabo12121164
Xu J, Zhang K, Qiu B, Liu J, Liu X, Yang S, Xiao X. Decreased Hyocholic Acid and Lysophosphatidylcholine Induce Elevated Blood Glucose in a Transgenic Porcine Model of Metabolic Disease. Metabolites. 2022; 12(12):1164. https://doi.org/10.3390/metabo12121164
Chicago/Turabian StyleXu, Jianping, Kaiyi Zhang, Bintao Qiu, Jieying Liu, Xiaoyu Liu, Shulin Yang, and Xinhua Xiao. 2022. "Decreased Hyocholic Acid and Lysophosphatidylcholine Induce Elevated Blood Glucose in a Transgenic Porcine Model of Metabolic Disease" Metabolites 12, no. 12: 1164. https://doi.org/10.3390/metabo12121164